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A report on the Cold Spring Harbor Laboratory meeting
‘Mechanisms of eukaryotic transcription’, Cold Spring
Harbor, USA, 2 August-2 September 2007.
It is becoming increasingly clear that the mechanisms gover-
ning eukaryotic transcription are as diverse and complex as the
organisms in which they are studied. The recent Cold Spring
Harbor Laboratory meeting on mechanisms of eukaryotic
transcription covered various topics, including epigenetics, the
architecture and regulation of the chromatin landscape
through histone modifications, and the mechanisms of
transcription initiation and elongation by RNA polymerase II
(Pol II). Here we report on the latter two topics, attempting to
integrate chromatin and Pol II regulatory mechanisms.
Chromatin architecture and histone crosstalk
networks
How nucleosomes are organized throughout a genome sets
the stage on which the transcription machinery engages each
and every gene. Complete high-resolution maps of nucleo-
some locations and their modifications are now coming to
light through high-resolution and data-intensive technolo-
gies such as chromatin immunoprecipitation followed by
sequencing or microarray identification of the pulled-down
DNA (ChIP-seq or ChIP-chip, respectively).
Keji Zhao (National Heart, Lung, and Blood Institute, NIH,
Bethesda, USA) reported work on the genome-wide distribu-
tions of numerous histone modifications and the histone
variant H2A.Z in human cells. Using ChIP-seq, he found that
monomethylation of H3 lysine 9 (K9), H3K27, H3K79,
H4K20, and H2BK5 is associated with gene activation,
whereas trimethylation of H3K9, H3K27, and H3K79 is
linked to repression. He also found that H2A.Z was prefer-
entially found in promoter regions, consistent with previous
reports in yeast. One of us (B.F.P.) reported genome-wide
maps of nucleosome locations in Saccharomyces cerevisiae
and  Drosophila melanogaster obtained using ChIP-seq.
Their nucleosome organization was found to be remarkably
similar in many respects, including nucleosome-free regions
at the beginning and end of genes. However, flies place their
+1 nucleosome (the first nucleosome downstream of the
transcription start site) a bit further downstream than in
yeast, which leaves the transcription start site intrinsically
accessible in flies.
The chromatin landscape is peppered with numerous
posttranslational modifications to histone tails, which serve
in part to regulate Pol II as it engages and traverses genes.
Recent evidence has begun to delineate the regulatory
pathways controlling several histone modifications. The
Bur1-Bur2 kinase regulates Set2-catalyzed methylation of
H3K36 in the coding regions of transcriptionally active
genes, which can serve as a mark to recruit the Rpd3 histone
deacetylase (HDAC). Consequently, this pathway establishes
an inverse relationship between the levels of H3K36
methylation and histone acetylation at some genes. Karen
Arndt (University of Pittsburgh, USA) reported that yeast
Paf1 plays a role in regulating the trimethylation levels in
this pathway. Using ChIP assays in paf1 deletion and bur1
deletion mutants, she found that trimethylated H3K36 is
preferentially decreased at the 5’ ends of genes in these
mutants, whereas acetylation of H3 and H4 is increased.
Arndt proposed that the Bur1-Bur2 kinase functions up-
stream of the Paf1 complex to regulate H3K36 trimethyl-
ation and H3 and H4 acetylation at the 5’ ends of genes.
To prevent spurious initiation by Pol II within the coding
region, the Rpd3 complex (Rpd3S) maintains hypo-
acetylated coding regions by recognizing the H3K36
trimethyl mark via the chromodomain of its Eaf3 subunit.
The H4 histone acetyltransferase (HAT) NuA4 does not,
however, recognize trimethylated H3K36 despite sharing theEaf3 subunit. Bing Li (Stowers Institute, Kansas City, USA)
addressed this interesting question of how yeast NuA4 and
Rpd3S bind different histone-tail modifications despite both
having the Eaf3 subunit. Using electrophoretic mobility-shift
assays and domain-swap experiments, he showed that the
combinatorial binding of the plant homeodomain (PHD) of
the Rco1 subunit and the chromodomain of the Eaf3 subunit
of Rpd3S determines its affinity and specificity for nucleo-
some substrates.
The H3K4 trimethyl mark is enriched at promoter
nucleosomes of actively transcribed genes. H3K79 methyl-
ation is also associated with active genes, and plays a role in
heterochromatin silencing. H3K4 trimethylation by the
complex of proteins associated with the Set1 methylase
(COMPASS) and methylation of H3K79 by Dot1 are
dependent on monoubiquitination of H2B, which is directed
by the Rad6/Bre1 complex; the mechanisms underlying these
interdependencies are not known, however. Ali Shilatifard
(Stowers Institute) used a biochemical approach to investi-
gate the mechanism of such histone crosstalk. He has found
that a COMPASS complex purified from a yeast rad6
deletion strain had lost Cps35, the only subunit that is
essential for viability. Shilatifard showed that this complex
was defective in the di- and trimethylation of H3K4 in vitro,
suggesting that the Rad6/Bre1 complex regulates the activity
and stability of COMPASS. Surprisingly, he discovered that
Cps35 also directly interacts with Dot1, and is required for
H3K79 methylation by Dot1. This indicates that the Cps35
subunit of COMPASS translates the H2B monoubiquitina-
tion signal for COMPASS and Dot1 methylation of H3K4 and
H3K79, although how the numerous other epigenetic marks
communicate with one another remains to be determined.
Using a quantitative proteomics approach to identify readers
of histone marks in human cells, Marc Timmers (University
Medical Centre Utrecht, Utrecht, The Netherlands) showed
that the general transcription factor TFIID reads the H3K4
trimethyl mark via the PHD domain of the TAF3 subunit.
This interaction was stimulated by acetylation of H3K9 and
H3K14 (typical of an active promoter), suggesting that H3K4
trimethylation may retain TFIID at active promoters. The
extent to which the H3K4 trimethyl mark stabilizes TFIID-
promoter interactions remains unclear.
Mechanisms for regulating Pol II
The rate of Pol II recruitment is generally regarded as a
measure of the transcriptional output for a given promoter
and the rate-limiting step in transcription. In Drosophila,
however, notable exceptions include transcriptional regulation
via pausing of bound Pol II (promoter-proximal pausing) in
heat-shock genes and some proto-oncogenes. S. cerevisiae
does not appear to regulate genes via Pol II pausing. Several
laboratories have looked for evidence of paused Pol II
throughout the Drosophila genome and found that it is more
widespread than previously appreciated. Karen Adelman
(National Institute of Environmental Health Sciences,
Research Triangle Park, USA) has carried out a genome-
wide search for proximally paused Pol II in Drosophila
promoters by performing ChIP-chip with the Rpb3 subunit
of Pol II, and found that around 1,000 genes were enriched
with Pol II in the promoter but not throughout the coding
region, consistent with the signature distribution for
paused Pol II in flies. Additional techniques, such as
permanganate footprinting, negative elongation factor
(NELF) depletion, and ChIP-chip for the phosphorylated
Ser2 residue of the Pol II carboxy-terminal domain,
corroborated Pol II pausing. She found around 1,000 genes
associated with stalled polymerase, including genes
involved in development, reproduction, and responses to
stimuli such as heat stress, oxidative stress, ionizing
radiation, and the immune response. Adelman proposed
that paused Pol II maintains a local chromatin architecture
that is poised for regulated and rapid activation in
response to stimuli. David Gilmour (Pennsylvania State
University, University Park, USA) also conducted a
genome-wide survey in Drosophila  for paused Pol II, in
this case by analyzing the distributions of two NELF
subunits using ChIP-chip, and detected NELF in around
4,000 regions throughout the genome. Permanganate
footprinting, which measures strand separation and is the
most definitive assay for pausing, confirmed that more
than 75% of the NELF-bound loci contained paused Pol II,
leading Gilmour to estimate that at least 1,000 genes
harbor a paused Pol II. Interestingly, the genomic location
of these paused polymerases puts them abutting the +1
nucleosome, suggesting that the organization of
Drosophila nucleosomes may contribute to pausing.
The presence of a paused Pol II implies that the cell uses
specific mechanisms to release Pol II into a productive
elongation-active state. John Lis (Cornell University,
Ithaca, USA) concluded from cellular snapshot methods of
protein crosslinking and DNA footprinting in Drosophila
that changes in the chromatin structure at the heat-shock
protein locus HSP70 are dependent on binding of heat-
shock factor (HSF), and precede Pol II movement into the
coding region of the gene. He reported that inhibition of the
activating transcription elongation factor kinase, P-TEFb,
blocked the transition to elongation, suggesting that P-
TEFb plays a critical role in regulating Pol II pausing. David
Price (University of Iowa, Iowa City, USA) reported the use
of various in vitro transcription systems derived from
Drosophila to show that P-TEFb controls Pol II elongation
status by regulating the ability of TFIIF and NELF to engage
the elongation complex. He found that TFIIF alone was
unable to associate with a Pol II complex containing NELF
and the DRB sensitivity-inducing factor (DSIF). However,
P-TEFb action shifted the balance, by blocking NELF
retention and allowing TFIIF to bind to the productive
elongation complex.
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Genome Biology 2007, 8:319A recent genome-wide study in yeast found that Pol II was
broadly detected throughout the genome, suggesting that
more of the genome may be transcribed than previously
thought. The strongest evidence for widespread transcrip-
tion of most genes came from the distantly related fission
yeast Schizosaccharomyces pombe. Brad Cairns (University
of Utah, Salt Lake City, USA) has used whole-genome tiling
arrays to detect small matched DNA-RNA hybrids, thus
measuring the abundance of RNAs of all types. In addition to
detecting sense transcripts at most genes, he found that
many genes also produce antisense transcripts, and that islands
of transcription exist within regions of heterochromatin.
From yeast to human, the eukaryotic cell meshes numerous
levels of regulation to direct with exquisite precision
transcriptional programs that dictate decisions on cell fate or
respond to a rapidly changing environment. The emergence
of high-resolution whole-genome nucleosomal maps coupled
with the uncovering of histone crosstalk networks will
provide deeper insight into long-standing transcriptional
paradigms. Pol II is guided by many regulatory mechanisms
during transcriptional initiation, pausing, and elongation, and
thus understanding how the numerous Pol II-associated
factors govern its transcriptional status will be an important
focus of future studies. As distinctions between regulatory
mechanisms dissolve, how the regulation of eukaryotic
transcription is integrated in time and space will continue to
captivate. We look forward with interest to next year’s meeting.
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